What is the optimal curative treatment for a healthy man with stage IIB seminoma who has normal pulmonary function and prefers to avoid chemotherapy?

Treatment Recommendation for Stage IIB Seminoma

For a healthy man with stage IIB seminoma, normal pulmonary function, and preference to avoid chemotherapy, radiation therapy is the recommended treatment, delivering 30 Gy to the para-aortic and ipsilateral iliac field with an additional boost of 6 Gy to enlarged lymph nodes. 1

Primary Treatment Options

The 2023 European Association of Urology guidelines explicitly outline two treatment pathways for stage IIB seminoma 1:

Preferred Option: Chemotherapy

• 3 cycles of BEP (bleomycin, etoposide, cisplatin)
• 4 cycles of EP if bleomycin contraindicated

Alternative Option: Radiation Therapy

• 30 Gy (15 fractions of 2 Gy) to para-aortic and ipsilateral iliac field
• Additional boost of 6 Gy (3 fractions of 2 Gy) to enlarged lymph nodes

Why Radiation Therapy Fits This Patient

Given this patient's explicit preference to avoid chemotherapy and normal pulmonary function, radiation therapy represents the guideline-endorsed alternative that directly addresses his treatment goals 1. Recent high-quality evidence from 2025 demonstrates that radiation therapy achieves excellent outcomes in stage IIB seminoma with a 5-year relapse rate of only 10% for stage IIA and even lower for IIB (2/42 patients relapsed) 2. All patients who relapsed after radiation were successfully salvaged with chemotherapy 2.

Emerging Surgical Option: RPLND

A third option has emerged from recent prospective studies: primary retroperitoneal lymph node dissection (RPLND). The 2025 EAU expert panel review analyzed 296 patients across multiple prospective studies and found 3:

• Relapse rate of 16% overall (most within first 2 years)
• All relapses successfully salvaged with chemotherapy
• 90-97% preservation of antegrade ejaculation
• Low major complication rate (5-12% Clavien-Dindo ≥3a)
• 2-year relapse-free survival of 85% in the 2026 meta-analysis 4

However, RPLND is not yet included as a standard guideline recommendation 1 and should only be performed by experienced surgeons at high-volume testicular cancer centers 3.

Treatment Algorithm for This Patient

1. First-line recommendation: Radiation therapy (30 Gy + 6 Gy boost) 1

   • Respects patient preference to avoid chemotherapy
   • Guideline-endorsed alternative
   • Excellent 5-year outcomes (>90% disease control) 2
   • Favorable acute toxicity profile 2

2. Consider RPLND if:

   • Patient strongly motivated to avoid both chemotherapy AND radiation
   • Access to experienced surgeon at specialized center
   • Willing to accept 16% relapse risk with salvage chemotherapy backup 3
   • Understands this is investigational (not standard guideline care)

3. Chemotherapy remains backup for:

   • Relapse after radiation or surgery
   • 100% salvage rate documented 3, 2

Critical Caveats

Long-term toxicity considerations: Both chemotherapy and radiation carry risks of secondary malignancies and cardiovascular disease 3. The patient should be informed that:

• Radiation therapy has a well-established long-term safety profile
• Chemotherapy avoidance reduces exposure to bleomycin (pulmonary toxicity) and cisplatin (ototoxicity, nephrotoxicity, neuropathy)
• RPLND avoids systemic therapy but has 16% chance of eventually requiring salvage chemotherapy 3

Do not initiate treatment unless metastatic disease is unequivocal based on biopsy, increasing nodal size/number, or subsequent marker rise 1.

Follow-up intensity: Residual masses after radiation require imaging and tumor marker surveillance 1. PET imaging should only be performed ≥2 months after treatment completion for masses >3 cm to avoid false positives 1.